Arizona Retina and Vitreous Consultants

Phoenix, Arizona 85021-8880

0 studies enrolling now · 20 studies all time

What they study most

Diabetic Macular Edema, Diabetic Retinopathy, Geographic Atrophy, Geographic Atrophy of the Macula, Macular Degeneration, Macular Degeneration, Age-Related, Macular Edema, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Nonproliferative Diabetic Retinopathy, Retinal Vein Occlusion, Wet Macular Degeneration

Studies at this site

• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME — Running, not enrolling
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema — Completed
• A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) — Running, not enrolling
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy — Completed
• A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) — Stopped early
• Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD — Completed
• The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) — Completed
• Anti-VEGF Treatment for Prevention of PDR/DME — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO — Stopped early
• A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema — Completed
• PROMINENT-Eye Ancillary Study (Protocol AD) — Stopped early
• Treatment for CI-DME in Eyes With Very Good VA Study — Completed
• A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration — Completed